In this publication Scandion Oncology has collaborated with researchers at the University of Copenhagen to demonstrate that a combination of SCO-101 and docetaxel show synergistic interaction in drug resistant cancer cells. This study is a proof-of-concept study highlighting that a combination of SCO-101 and docetaxel showed an approximately 60% increase in potency compared to docetaxel alone. Furthermore, the results provided key information regarding promising dose ratios and dose levels for further studies of the combination.
This study was an international research collaborations aiming to investigate the effects and mechanisms of action for SCO-201. It was demonstrated that SCO-201 inhibits a protein belonging to the drug efflux transporters (ATP-binding cassette (ABC) transporters), thereby restoring the sensitivity of drug resistant cells by preventing the efflux of the chemotherapy. Additionally, SCO-201 did not affect the levels or activities of CYP (cytochrome P450) metabolizing enzymes, which is highly desirable for novel drug candidates.
This study was an international research collaborations within colon cancer. The study shows that, by measuring two biomarkers (ABCG2 and TOP1), it is possible to predict whether or not the chemotherapy agent irinotecan have a beneficial effect when combined with 5-FUL. The implication for Scandion Oncology is that biomarkers can be used to predict which patients may, or may not, respond to Scandion Oncology’s candidate drug SCO-101 when combined with iriontecan containg chemotherapy.